cpeb1 Antibody

What is CPEB1 and what cellular functions does it regulate?

CPEB1 is a sequence-specific RNA-binding protein that regulates mRNA cytoplasmic polyadenylation and translation initiation. It functions in diverse cellular processes including:

• Oocyte maturation and early development

• Neuronal function at postsynaptic sites

• Cell migration via cytoskeletal regulation

• Mammary epithelial cell differentiation

• Prevention of epithelial-to-mesenchymal transition (EMT)

• Cell cycle progression, specifically prophase entry

• Microglial inflammatory immune responses

CPEB1 recognizes the cytoplasmic polyadenylation element (CPE), an uridine-rich sequence (consensus 5'-UUUUUAU-3') within mRNA 3'-UTRs. Upon binding, CPEB1 undergoes a conformational change analogous to the Venus fly trap mechanism . Depending on its phosphorylation state, CPEB1 can either repress or activate translation of target mRNAs, providing a sophisticated control mechanism for protein synthesis .

What detection applications are CPEB1 antibodies validated for?

CPEB1 antibodies have been validated for multiple applications as summarized in the table below:

When selecting an application, consider that antibody performance may vary between species and cellular contexts. Validation in your specific experimental system is recommended before extensive use .

How should I validate a CPEB1 antibody in my experimental system?

Proper validation of CPEB1 antibodies requires a multi-faceted approach:

• Specificity testing: Compare signal in wild-type cells versus CPEB1-knockdown or knockout cells. The antibody should show diminished signal in the absence of CPEB1.

• Molecular weight verification: CPEB1 has a molecular weight of approximately 62 kDa. In Western blots, verify that your antibody detects a band of the correct size .

• Phosphorylation state discrimination: If studying phosphorylated CPEB1, validate that your phospho-specific antibody distinguishes between phosphorylated and unphosphorylated forms by comparing ratios of phospho-CPEB1 to total CPEB1 .

• Cross-reactivity assessment: Ensure the antibody does not cross-react with other CPEB family members (CPEB2-4) by testing in systems with known expression profiles of these proteins.

• Positive control tissues: Test the antibody in tissues known to express CPEB1, such as brain tissue for neuronal CPEB1 or mammary epithelial tissue .

The most rigorous validation includes detecting loss of signal following genetic knockdown using techniques such as shRNA, as demonstrated in studies of mammary epithelial cells .

How can I optimize CPEB1 immunofluorescence for co-localization studies with β-catenin?

Co-localization studies between CPEB1 and β-catenin require careful optimization:

• Fixation protocol: Use 4% paraformaldehyde in PBS with 4% sucrose, as this preserves both membrane-associated β-catenin and CPEB1 structures .

• Blocking conditions: Block with 10% horse serum for at least 15 minutes to reduce background and non-specific binding .

• Antibody selection: Choose antibodies raised in different host species (e.g., rabbit anti-CPEB1 and mouse anti-β-catenin) to enable simultaneous detection with species-specific secondary antibodies .

• Antibody dilutions: For optimal results, use anti-β-catenin at 1:1000 and anti-CPEB1 at 1:1000 for overnight incubation at 4°C .

• Secondary antibody selection: Use species-specific secondary antibodies conjugated to spectrally distinct fluorophores (e.g., FITC and Cy3) to clearly differentiate signals .

• Imaging controls: Include single-label controls and no-primary-antibody controls to assess bleed-through and background fluorescence.

This protocol has been successfully used to demonstrate co-localization of CPEB1 and β-catenin at the leading edge of migrating astrocytes, suggesting functional interaction between these proteins in cell migration .

What protocol should I use for CPEB1 immunoprecipitation to study associated mRNAs?

For effective immunoprecipitation (IP) of CPEB1-bound mRNAs, follow this optimized protocol:

• Cell preparation: Grow cells to approximately 70% confluence in appropriate culture vessels .

• Lysis conditions: Lyse cells in buffer containing 10 mM HEPES pH 7.4, 200 mM NaCl, 30 mM EDTA, and 0.5% Triton X-100 supplemented with 200 U/ml RNase inhibitor to preserve RNA integrity .

• Antibody binding: Add anti-CPEB1 antibody (or rabbit IgG as control) and incubate for 2 hours at room temperature with gentle rotation .

• Bead preparation: Equilibrate Protein A-agarose beads in lysis buffer, then add to the antibody-lysate mixture and incubate with rotation for 30 minutes .

• Washing: Isolate beads by centrifugation and wash 6 times with wash buffer containing 10 mM HEPES pH 7.4, 500 mM NaCl, 30 mM EDTA, and 0.5% Triton X-100 .

• RNA extraction: Extract RNA from the immunoprecipitate using an appropriate RNA isolation kit (e.g., Qiagen RNeasy) .

• Analysis: Reverse transcribe recovered RNA and perform PCR or qRT-PCR for suspected target mRNAs.

Alternative approach: For identifying novel CPEB1 targets, you can use a 6x-His-tagged CPEB1 RNA-binding domain (CPEB1-RBD) construct, which can be purified with metal affinity chromatography (e.g., Talon beads) after cell lysis .

This approach has successfully identified β-catenin mRNA as a CPEB1 target in astrocytes, demonstrating its utility in discovering functional CPEB1-mRNA interactions .

How can I study CPEB1's role in mammary epithelial cell differentiation and EMT?

To investigate CPEB1's function in mammary epithelial differentiation and EMT:

• Cell models: Use mammary epithelial cell lines like CID-9, which contain both myoepithelial and luminal epithelial cells, or purified subpopulations (SCp2 for luminal epithelial cells, SCg6 for myoepithelial cells) .

• Knockdown approach:

  • Generate stable CPEB1-knockdown cells using specific shRNAs

  • Validate knockdown efficiency by Western blot using antibodies against total CPEB1 (1:2500 dilution)

• EMT marker analysis: Assess expression of:

  • Epithelial markers: E-cadherin, β-catenin

  • Mesenchymal markers: vimentin, Twist1

  • Myoepithelial marker: p63

• 3D culture assay:

  • Culture cells on Matrigel with insulin, prolactin, and hydrocortisone

  • Monitor acini formation and cellular organization

  • Examine E-cadherin localization by immunofluorescence

• Migration assays: Compare motility between control and CPEB1-depleted cells to assess functional consequences of EMT .

• Translation regulation analysis:

  • Measure poly(A) tail length of suspected target mRNAs

  • Perform polysome profiling to assess translation efficiency

  • Use luciferase reporter assays with wild-type and mutated 3'-UTRs

This comprehensive approach revealed that CPEB1 prevents EMT by translationally silencing Twist1 in myoepithelial cells, which in turn influences the polarity and proliferation of luminal epithelial cells .

What are the key considerations when detecting phosphorylated versus total CPEB1?

When distinguishing between phosphorylated and total CPEB1:

• Antibody selection:

  • Use phospho-specific antibodies that recognize the specific phosphorylation site of interest

  • For total CPEB1, choose antibodies targeting regions away from known phosphorylation sites

  • Standard dilutions: Phospho-CPEB1 (1:5000) and total CPEB1 (1:2500)

• Sample preparation:

  • Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in lysis buffers

  • Process samples quickly and maintain cold temperatures to preserve phosphorylation status

  • Consider lambda phosphatase treatment of control samples to verify phospho-specificity

• Quantification approach:

  • Always normalize phospho-CPEB1 signal to total CPEB1 signal

  • Use femto ECL for detection to capture the full dynamic range of signals

  • Analyze using densitometry software (e.g., EpiChemi II Darkroom and Labworks software)

• Technical considerations:

  • Phosphorylation may alter CPEB1 mobility on SDS-PAGE

  • Multiple phosphorylation states may result in multiple bands

  • Different cell types may show different basal phosphorylation levels

This approach allows accurate assessment of changes in CPEB1 phosphorylation status, which is crucial since phosphorylation dramatically alters CPEB1's function from a translational repressor to an activator .

How do I troubleshoot variable CPEB1 detection across different cell types?

When facing inconsistent CPEB1 detection across cell types, consider these troubleshooting approaches:

• Cell type-specific expression levels:

  • CPEB1 expression varies significantly between cell types

  • In mammary tissue, CPEB1 is predominantly expressed in myoepithelial cells rather than luminal epithelial cells

  • Adjust protein loading or antibody concentration accordingly

• Isoform detection:

  • Verify which CPEB1 isoforms your antibody recognizes

  • Choose antibodies targeting conserved regions if detecting all isoforms is desired

  • Consider antibodies targeting specific regions (e.g., aa 1-486, aa 282-561, aa 311-561) for isoform specificity

• Sample preparation optimization:

  • Adjust lysis conditions based on subcellular localization (CPEB1 can be cytoplasmic or nuclear)

  • For membrane-associated CPEB1, ensure sufficient detergent in lysis buffer

  • For stress granule-associated CPEB1, consider specialized extraction protocols

• Signal amplification:

  • For low-expressing cells, use HRP-conjugated secondary antibodies with enhanced chemiluminescence

  • Consider tyramide signal amplification for immunofluorescence

  • Use biotin-conjugated antibodies with streptavidin detection systems

• Validation strategy:

  • Use positive control cell lines with known CPEB1 expression

  • Include CPEB1 knockdown/knockout controls specific to each cell type

  • Consider RT-PCR to verify mRNA expression before protein detection

These approaches account for the biological variation in CPEB1 expression and localization across cell types, which can significantly impact detection sensitivity and specificity.

How can I use CPEB1 antibodies to study its role in neuronal function?

To investigate CPEB1's role in neuronal systems:

• Subcellular localization:

  • Use immunofluorescence to detect CPEB1 in dendrites and at synapses

  • Co-stain with synaptic markers (PSD-95, synaptophysin) to assess enrichment at synaptic sites

  • Consider super-resolution microscopy for precise localization

• Activity-dependent regulation:

  • Stimulate neurons (e.g., glutamate, BDNF, electrical stimulation) and assess changes in CPEB1 phosphorylation

  • Use phospho-specific antibodies to monitor activation status

  • Correlate with synaptic plasticity markers

• mRNA transport studies:

  • Use CPEB1 antibodies for immunoprecipitation followed by RNA-seq to identify transported mRNAs

  • Examine colocalization with RNA transport granules using RNA FISH combined with CPEB1 immunofluorescence

  • CPEB1 is involved in transporting CPE-containing mRNAs to dendrites in a translationally dormant form

• Translation regulation:

  • Use polysome profiling combined with CPEB1 immunoprecipitation

  • Assess interactions with translation factors (eIF2α) using proximity ligation assays

  • CPEB1 works alongside proteins like eIF2α to enhance synaptic strength and memory formation

CPEB1's function in neurons is particularly important for local protein synthesis at synapses, which impacts synaptic function and plasticity crucial for learning and memory processes .

What approaches should I use to study CPEB1 in inflammatory responses?

When investigating CPEB1's role in inflammatory responses:

• Cell systems:

  • Focus on microglial cells, which are the primary immune cells of the CNS

  • Consider comparing CPEB1 wild-type and knockout/knockdown microglia

  • CPEB1 regulates microglial inflammatory response and phagocytosis

• Stimulation conditions:

  • Treat cells with inflammatory stimuli (LPS, TNF-α, IL-1β)

  • Assess dose-dependent and time-course responses

  • Compare acute versus chronic inflammatory conditions

• Detection methods:

  • Monitor CPEB1 expression and phosphorylation status via Western blotting

  • Use immunofluorescence to assess subcellular localization changes during inflammation

  • Employ flow cytometry for quantitative single-cell analysis

• Functional assays:

  • Measure inflammatory cytokine production (ELISA, qPCR)

  • Assess phagocytic activity using fluorescent beads or labeled cellular debris

  • Evaluate morphological changes associated with microglial activation

• Target identification:

  • Perform CPEB1 immunoprecipitation followed by RNA-seq under inflammatory conditions

  • Focus on mRNAs encoding inflammatory mediators

  • Validate translational regulation using reporter assays

This approach has revealed that CPEB1 is a key regulator of microglial inflammatory response and phagocytosis, with significant implications for neuroinflammatory disorders .

How can I distinguish between CPEB family members in my experiments?

To effectively distinguish between CPEB1 and other family members (CPEB2-4):

• Antibody selection:

  • Choose antibodies targeting non-conserved regions of CPEB1

  • Avoid antibodies targeting the RNA recognition motif (RRM), which is conserved

  • C-terminal and N-terminal regions offer greater specificity

• Validation approach:

  • Test antibodies in overexpression systems for each CPEB family member

  • Include CPEB1-4 knockout/knockdown controls

  • Verify specificity via immunoblotting, checking for single bands of the correct molecular weight

• Expression pattern analysis:

  • Different CPEB family members show distinct tissue and developmental expression patterns

  • CPEB1 is predominantly expressed in oocytes, neurons, and specific epithelial cells

  • Use tissue-specific positive controls to benchmark antibody performance

• Functional discrimination:

  • CPEB1 binds to the canonical CPE sequence (UUUUUAU)

  • Other family members may recognize variant CPE sequences

  • Consider RNA-binding specificity when interpreting results

• Phosphorylation state:

  • CPEB1 phosphorylation sites differ from those in other family members

  • Phospho-specific antibodies can provide additional discrimination

  • Different kinases target different CPEB proteins

By combining these approaches, researchers can ensure specific detection of CPEB1 without cross-reactivity with other CPEB family members, which is essential for accurate interpretation of experimental results.

What are the optimal storage and handling conditions for CPEB1 antibodies?

For maximum longevity and performance of CPEB1 antibodies:

• Storage temperature:

  • Store antibody aliquots at -20°C for long-term storage

  • Avoid repeated freeze-thaw cycles (limit to <5)

  • Working aliquots can be stored at 4°C for up to 2 weeks

• Aliquoting strategy:

  • Divide antibodies into single-use aliquots upon receipt

  • Typical aliquot volumes: 10-20 μL depending on application

  • Include date of aliquoting and number of freeze-thaw cycles on labels

• Buffer considerations:

  • Most CPEB1 antibodies are supplied in PBS with preservatives

  • Some contain glycerol (typically 50%) for cryoprotection

  • Avoid diluting stock antibodies unless immediately using

• Handling precautions:

  • Keep on ice when in use

  • Centrifuge briefly before opening vials to collect liquid

  • Use sterile technique to prevent microbial contamination

• Working dilution preparation:

  • Prepare fresh working dilutions for each experiment

  • Dilute in blocking buffer containing 1-5% BSA or serum

  • For Western blotting, consider adding 0.05% sodium azide to working dilutions for reuse

Proper storage and handling significantly impact antibody performance and reproducibility across experiments .

How do I optimize CPEB1 antibody concentration for different detection methods?

Optimal antibody concentrations vary by application:

• Western Blotting:

  • Starting dilution: 1:1000 to 1:5000

  • For phospho-CPEB1: typically 1:5000

  • For total CPEB1: typically 1:2500

  • Optimize by testing serial dilutions (e.g., 1:1000, 1:2500, 1:5000, 1:10000)

• Immunofluorescence/IHC:

  • Starting dilution: 1:100 to 1:1000

  • Optimal dilution for cell lines: 1:1000

  • Higher concentrations may be needed for tissue sections

  • Include antigen retrieval optimization for fixed tissues

• Immunoprecipitation:

  • Typically 2-5 μg antibody per 1 mg total protein

  • Verify efficiency by immunoblotting supernatant after IP

• ELISA:

  • Capture antibody: 1-10 μg/mL

  • Detection antibody: 0.1-1 μg/mL

  • Perform checkerboard titration to determine optimal concentrations

• Flow cytometry:

  • Starting concentration: 1 μg per 10^6 cells

  • Include appropriate isotype controls at matching concentrations

• Titration strategy:

  • Begin with manufacturer's recommended dilution

  • Test 2-fold serial dilutions above and below recommendation

  • Select dilution that maximizes specific signal while minimizing background

Optimal antibody concentration depends on the specific antibody clone, sample type, and detection system. It's recommended to perform titration experiments for each new experimental system .

How can CPEB1 antibodies help elucidate its role in EMT and cancer research?

CPEB1 antibodies have been instrumental in revealing its function as an EMT suppressor:

• Expression correlation studies:

  • CPEB1 levels inversely correlate with EMT markers in mammary epithelial cells

  • CPEB1 knockdown decreases E-cadherin and β-catenin while increasing vimentin and Twist1

  • Detection requires reliable antibodies for both CPEB1 and EMT markers

• Mechanistic investigations:

  • CPEB1 antibodies used in RNA immunoprecipitation revealed direct binding to Twist1 mRNA

  • This binding leads to poly(A) tail shortening and translational repression

  • CPEB1 predominantly expresses in myoepithelial cells and regulates their differentiation

• Functional assays:

  • CPEB1-depleted cells show increased motility

  • In 3D culture, CPEB1-deficient cells form disorganized, proliferating colonies lacking polarization and central cavity

  • These phenotypes are consistent with EMT and potential malignant transformation

• Cell-type specific effects:

  • In mixed cultures, CPEB1 increases during differentiation

  • In pure cell populations, CPEB1 depletion increases Twist1 only in myoepithelial cells (SCg6)

  • CPEB1 knockdown fails to downregulate E-cadherin in pure luminal epithelial cells (SCp2)

These findings highlight CPEB1's potential tumor-suppressive role, suggesting that myoepithelial cells prevent EMT by influencing luminal epithelial cells through a mechanism requiring translational silencing of Twist1 by CPEB1 .

What is the recommended protocol for studying CPEB1 in 3D culture systems?

For studying CPEB1 in 3D culture systems:

• Cell preparation:

  • Culture CID-9 or other mammary epithelial cells to approximately 70% confluence

  • For CPEB1 knockdown studies, generate stable lines expressing CPEB1 shRNA

  • Include appropriate control shRNA lines

• 3D culture setup:

  • Plate cells on Matrigel (growth factor-reduced)

  • Supplement media with differentiation factors: insulin, prolactin, and hydrocortisone

  • Monitor differentiation for 1, 2, 5, and 8 days

• Morphological analysis:

  • Track formation of 3D acini using phase contrast microscopy

  • Normal cells cease proliferation and form polarized structures with central cavities

  • CPEB1-deficient cells form disorganized structures and continue to proliferate

• Immunofluorescence procedure:

  • Fix 3D structures with 4% paraformaldehyde in PBS with 4% sucrose

  • Block with 10% horse serum for 15 minutes

  • Incubate with primary antibodies overnight at 4°C (e.g., E-cadherin, β-catenin, CPEB1)

  • Wash thoroughly and incubate with appropriate secondary antibodies

  • Mount using Vectashield mounting medium

• Analysis parameters:

  • Assess polarization through E-cadherin localization at lateral cell surfaces

  • Evaluate cavity formation as indicator of proper differentiation

  • Compare proliferation rates between control and CPEB1-deficient structures

  • Quantify differentiation markers (e.g., β-casein expression)